IL17A and inflammatory bowel disease: Additionally, SCFAs may inhibit histone deacetylases HDAC1 or HDAC3, suppressing interleukin 17 (IL-17) production by γδT cells in the colon and cecum, enhancing our understanding of γδT cells regulation and offering new therapeutic avenues for IBD [117].